Thursday, August 11, 2016 12:28:32 PM
While the United States government refuses to admit the cannabis plant has any real medicinal benefit, its position has not prevented federal health agencies, over the years, from approving synthetic versions of the herb’s psychoactive component to be used by Big Pharma in the treatment of serious conditions.
In fact, the U.S. Food and Drug Administration (FDA), one of the primary barriers in the grand scheme of nationwide legalization, recently approved a liquid variety of synthetic tetrahydrocannabidiol (THC) that will be sold to people suffering from AIDS and cancer.
It was revealed earlier this month that Insys Therapeutics is gearing up to go after a piece of the medical marijuana market, one reportedly worth hundreds of millions of dollars, with a new FDA-approved form of dronabinol. This first-of-a-kind liquid THC synthetic, set to be stocked on pharmacy shelves under the name Syndros, has been given the green light for the treatment of “anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.”
Recent CBDS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:58:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:34:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 07:44:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 07:24:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:46:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:39:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:22:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 05:09:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/07/2024 08:05:49 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 02/06/2024 08:19:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 12:01:39 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 08:08:10 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 04:21:57 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 09/05/2023 07:09:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 04:03:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM